Female Pelvic Blood Flow Under Simulated Microgravity
Launched by CEREN UNAL · Oct 7, 2024
Trial Information
Current as of July 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how simulated microgravity affects blood flow in the pelvic area of healthy women. Researchers want to understand how space travel might impact women's health, particularly the blood circulation to reproductive organs like the uterus and ovaries. To do this, they will use a method called Doppler velocimetry, which helps measure blood flow. Participants will first lie flat (the supine position) to establish a baseline measurement of their blood flow. Then, they will be placed in a head-down tilt position, which simulates the effects of microgravity, and blood flow will be measured again.
Women aged 18 to 44 who are generally healthy can join this study. However, those who have had a hysterectomy (removal of the uterus) or oophorectomy (removal of the ovaries), are pregnant, have certain reproductive health issues, or heart diseases cannot participate. Throughout the trial, participants will have their vital signs, like blood pressure and heart rate, monitored. This study is important as it helps us learn more about how space travel may affect women's health, especially with upcoming missions to the Moon and Mars.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 18-44 years old healthy female individuals
- Exclusion Criteria:
- • History of hysterectomy and/or oophorectomy
- • Pregnancy
- • Premature ovarian insufficiency
- • Women with reproductive tract pathologies
- • Cardiovascular diseases
About Ceren Unal
Ceren Unal is a dedicated clinical trial sponsor specializing in the design, management, and execution of innovative clinical research initiatives. With a strong commitment to advancing medical knowledge and improving patient outcomes, Ceren Unal collaborates with a diverse range of stakeholders, including pharmaceutical companies, academic institutions, and healthcare providers. The organization emphasizes rigorous scientific methodology and ethical standards in its trials, ensuring the highest quality of data collection and analysis. Through its strategic approach and expertise in clinical development, Ceren Unal aims to accelerate the delivery of new therapies to the market, ultimately enhancing the standard of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Trial Officials
Afak Durur Karakaya, M.D.
Principal Investigator
Koç University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported